GleamWall
中文EN

CBIO CRESCENT BIOPHARMA, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1253689 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-58.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,216.6%
Net margin-727.6%
FCF margin-549.5%
EBITDA margin-1,214.9%

Returns

ROE-55.8%
ROA-49.9%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets8.4%
Debt / equity0.00x
Current ratio12.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-12.4%
Payout ratio—
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$3.12M$0$1.04M$10.84M$0$0$0$0
R&D expense$34.30M$19.39M$17.90M$95.03M$20.35M$12.08M$10.63M$14.03M
SG&A expense$8.72M$8.74M$7.87M$7.31M$5.54M$8.95M$3.60M$3.16M
Operating income-$39.91M-$26.36M-$24.73M-$91.49M-$25.89M-$21.03M-$14.22M-$17.19M
Interest expense$0$0$0$0$0$1.07M$1.11M$852,000
Pretax income———————-$17.87M
Income tax$0$0$0$2.00M$0$0$0$0
Net income-$37.73M-$24.84M-$23.28M-$23.30M-$24.61M-$21.79M-$15.15M-$7.22M
EBITDA-$39.84M-$26.30M-$24.66M-$91.44M-$25.86M-$21.03M-$14.22M-$17.19M
EPS (basic)——————-0.04—
EPS (diluted)————————
Balance sheet
Cash & equivalents$289.36M$171.59M$189.16M$213.19M$133.26M$152.65M$22.43M$34.77M
Receivables$0$0$0$18.00M———$0
Current assets$295.21M$179.01M$195.56M$236.66M$134.56M$154.23M$5.99M$34.80M
PP&E, net$809,000$876,000$929,000$846,000$782,000$193,000—$0
Total assets$299.50M$182.76M$199.13M$240.29M$138.27M$157.43M$5.99M$35.62M
Current liabilities$23.49M$18.54M$14.19M$36.07M$20.30M$16.75M$2.62M$9.61M
Total liabilities$25.22M$19.50M$15.28M$37.28M$21.63M$18.18M$2.62M$47.10M
Shareholders' equity$274.28M$163.25M$183.85M$203.01M$116.64M$139.25M-$30.16M-$15.48M
Shares outstanding38.18M27.76M27.57M27.56M13.89M13.89M64.53M1.02M
Cash flow statement
Operating cash flow-$26.94M-$19.46M-$8.94M-$26.74M-$17.54M-$22.15M-$10.85M-$6.27M
Capital expenditure$0$13,000$147,000$193,000$586,000$140,000$0$0
Free cash flow-$26.94M-$19.48M-$9.08M-$26.93M-$18.12M-$22.29M-$10.85M-$6.27M
Investing cash flow$0$1.76M-$8.15M-$72.19M-$586,000-$140,000$0$0
Financing cash flow$144.81M$136,000-$6.95M$178.86M-$1.25M$146.86M-$1.49M$41.03M
Depreciation & amortization$67,000$66,000$64,000$54,000$28,000$2,000$0$0
Stock-based compensation$4.22M$3.96M$4.11M$4.75M$1.99M$5.34M$1.23M$1.13M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.